FORT LAUDERDALE, FL, QC — October 16, 2025 — Leads & Copy — Sunshine Biopharma Inc. (NASDAQ:SBFM) announced today that its Canadian subsidiary, Nora Pharma Inc., has launched Pravastatin, a generic prescription drug used for Lipid Metabolism Regulation.
Pravastatin, a generic version of Pravachol®, is a statin medication that lowers bad cholesterol (LDL) and increases good cholesterol (HDL), helping to prevent heart attacks, strokes, and other cardiovascular conditions. Nora Pharma’s Pravastatin is available in strengths of 10 mg, 20 mg, and 40 mg, in bottles of 100 tablets. According to IQVIA, the Canadian market for cholesterol-lowering drugs is estimated to reach USD $582 million by the end of 2025 and is expected to expand at a CAGR of 8% per year, reaching USD $1.07 billion by 2033. Globally, Biospace projects the lipid-lowering drugs market size to surpass USD $46.58 billion by 2033.
“We are excited to introduce Pravastatin to the market,” said Steve Slilaty, CEO of Sunshine Biopharma. “This launch reinforces our dedication to improving patient outcomes through innovative therapies that address critical health needs.”
Sunshine Biopharma currently has 74 generic prescription drugs on the market in Canada and more than 12 additional drugs scheduled to be launched in 2026. Sunshine Biopharma is also developing K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections.
Camille Sebaaly, CFO can be reached at 514-814-0464 or camille.sebaaly@sunshinebiopharma.com
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the “Company”) that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company’s drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company’s filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company’s most recent SEC filings.
Source: Sunshine Biopharma Inc.
